亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

医学 蛋白尿 达帕格列嗪 肾脏疾病 肾功能 微量白蛋白尿 泌尿科 内科学 2型糖尿病 糖尿病 安慰剂 肌酐 内分泌学 病理 替代医学
作者
Niels Jongs,Tom Greene,Glenn M. Chertow,John J.V. McMurray,Anna Maria Langkilde,Ricardo Correa‐Rotter,Peter Rossing,C. David Sjöström,Bergur V. Stefánsson,Robert D. Toto,David C. Wheeler,Hiddo J.L. Heerspink
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier]
卷期号:9 (11): 755-766 被引量:124
标识
DOI:10.1016/s2213-8587(21)00243-6
摘要

Background Reductions in albuminuria are associated with a subsequent lower risk of kidney failure in patients with chronic kidney disease. The SGLT2 inhibitor dapagliflozin significantly reduced albuminuria in patients with type 2 diabetes and normal or near-normal kidney function. Whether this effect persists in patients with chronic kidney disease with and without type 2 diabetes is unknown. We assessed the effects of dapagliflozin on albuminuria in patients with chronic kidney disease with and without type 2 diabetes in the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. Methods DAPA-CKD was a multicentre, double-blind, placebo-controlled, randomised trial done at 386 sites in 21 countries. Patients were eligible for the trial if they had chronic kidney disease, defined as an estimated glomerular filtration rate (eGFR) between 25 mL/min per 1·73 m2 and 75 mL/min per 1·73 m2 and a urinary albumin-to-creatinine ratio (UACR) between 200 mg/g and 5000 mg/g (22·6 to 565·6 mg/mmol). Participants were randomly assigned to dapagliflozin 10 mg (AstraZeneca; Gothenburg, Sweden) once daily or matching placebo, in accordance with the sequestered, fixed randomisation schedule, using balanced blocks to ensure an approximate 1:1 ratio. Change in albuminuria was a pre-specified exploratory outcome of DAPA-CKD. Regression in UACR stage, defined as a transition from macroalbuminuria (≥300 mg/g) to microalbuminuria or normoalbuminuria (<300 mg/g), and progression in UACR stage, defined as a transition from less than 3000 mg/g to 3000 mg/g or greater, were additional discrete endpoints. The trial is registered with ClinicalTrials.gov, NCT03036150. Findings Between Feb 2, 2017, and April 3, 2020, 4304 patients were recruited and randomly assigned to either dapagliflozin (n=2152) or placebo (n=2152). Median UACR was 949 mg/g (IQR 477 to 1885). Overall, compared with placebo, dapagliflozin reduced geometric mean UACR by 29·3% (95% CI –33·1 to –25·2; p<0·0001); relative to placebo, treatment with dapagliflozin resulted in a geometric mean percentage change of −35·1% (95% CI −39·4 to −30·6; p<0·0001) in patients with type 2 diabetes and −14·8% (−22·9 to −5·9; p=0·0016) in patients without type 2 diabetes over the follow-up visits (pinteraction<0·0001) Among 3860 patients with UACR of 300 mg/g or greater at baseline, dapagliflozin increased the likelihood of regression in UACR stage (hazard ratio 1·81, 95% CI 1·60 to 2·05). Among 3820 patients with UACR less than 3000 mg/g at baseline, dapagliflozin decreased the risk of progression in UACR stage (0·41, 0·32 to 0·52). Larger reductions in UACR at day 14 during dapagliflozin treatment were significantly associated with attenuated eGFR decline during subsequent follow-up (β per log unit UACR change –3·06, 95% CI –5·20 to –0·90; p=0·0056). Interpretation In patients with chronic kidney disease with and without type 2 diabetes, dapagliflozin significantly reduced albuminuria, with a larger relative reduction in patients with type 2 diabetes. The similar effects of dapagliflozin on clinical outcomes in patients with or without type 2 diabetes, but different effects on UACR, suggest that part of the protective effect of dapagliflozin in patients with chronic kidney disease might be mediated through pathways unrelated to reduction in albuminuria. Funding AstraZeneca.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
WANG发布了新的文献求助10
1分钟前
Krim完成签到 ,获得积分10
1分钟前
1分钟前
落后从阳完成签到 ,获得积分10
2分钟前
3分钟前
瓜皮糖浆发布了新的文献求助30
4分钟前
港港完成签到 ,获得积分10
4分钟前
4分钟前
瓜皮糖浆完成签到,获得积分10
4分钟前
浅黑色饕餮完成签到,获得积分10
4分钟前
斯文败类应助浅黑色饕餮采纳,获得10
4分钟前
拜托你清醒一点完成签到 ,获得积分10
4分钟前
lelecha发布了新的文献求助10
4分钟前
4分钟前
zs完成签到 ,获得积分10
4分钟前
lelecha完成签到,获得积分10
5分钟前
5分钟前
风起云涌龙完成签到 ,获得积分0
6分钟前
bkagyin应助科研通管家采纳,获得10
6分钟前
mellow发布了新的文献求助10
7分钟前
Aloha完成签到 ,获得积分10
7分钟前
熊一只发布了新的文献求助10
8分钟前
nanfang完成签到 ,获得积分10
8分钟前
光亮的自行车完成签到 ,获得积分10
8分钟前
Qvby3完成签到 ,获得积分10
8分钟前
领导范儿应助科研通管家采纳,获得10
8分钟前
可爱的函函应助Jenaloe采纳,获得10
9分钟前
9分钟前
9分钟前
9分钟前
Jenaloe发布了新的文献求助10
9分钟前
Jenaloe完成签到,获得积分10
9分钟前
9分钟前
落后的西牛完成签到 ,获得积分10
10分钟前
Artin完成签到,获得积分10
10分钟前
深情安青应助科研通管家采纳,获得10
10分钟前
xzn发布了新的文献求助10
11分钟前
Rebeccaiscute完成签到 ,获得积分10
11分钟前
WANG发布了新的文献求助10
12分钟前
小王完成签到 ,获得积分10
12分钟前
高分求助中
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
Retention of title in secured transactions law from a creditor's perspective: A comparative analysis of selected (non-)functional approaches 500
"Sixth plenary session of the Eighth Central Committee of the Communist Party of China" 400
Introduction to Modern Controls, with illustrations in MATLAB and Python 310
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3056457
求助须知:如何正确求助?哪些是违规求助? 2713069
关于积分的说明 7434540
捐赠科研通 2358102
什么是DOI,文献DOI怎么找? 1249268
科研通“疑难数据库(出版商)”最低求助积分说明 607010
版权声明 596195